LT2373681T - Albiglutido farmacinės kompozicijos - Google Patents

Albiglutido farmacinės kompozicijos

Info

Publication number: LT2373681T
Authority: LT; Lithuania
Prior art keywords: albiglutide; pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2008-12-10

Application number

LTEP09832522.8T

Other languages

English (en)

Inventor

Mark A. Bush

Murray W. Stewart

Yonghong Yang

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-10

Filing date

2009-12-10

Publication date

2017-04-10

2009-12-10 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2017-04-10 Publication of LT2373681T publication Critical patent/LT2373681T/lt

Links

OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical group O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 title 1
229960004733 albiglutide Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
108700027806 rGLP-1 Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Hematology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTEP09832522.8T 2008-12-10 2009-12-10 Albiglutido farmacinės kompozicijos LT2373681T (lt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12122908P	2008-12-10	2008-12-10
US15090909P	2009-02-09	2009-02-09
US16399509P	2009-03-27	2009-03-27
US23872309P	2009-09-01	2009-09-01
PCT/US2009/067469 WO2010068735A1 (en)	2008-12-10	2009-12-10	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
LT2373681T true LT2373681T (lt)	2017-04-10

Family

ID=42243062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP09832522.8T LT2373681T (lt)	2008-12-10	2009-12-10	Albiglutido farmacinės kompozicijos

Country Status (14)

Country	Link
US (3)	US8748377B2 (lt)
EP (1)	EP2373681B1 (lt)
JP (1)	JP2012511586A (lt)
CY (1)	CY1118731T1 (lt)
DK (1)	DK2373681T3 (lt)
ES (1)	ES2620610T3 (lt)
HR (1)	HRP20170478T1 (lt)
HU (1)	HUE031900T2 (lt)
LT (1)	LT2373681T (lt)
PL (1)	PL2373681T3 (lt)
PT (1)	PT2373681T (lt)
SI (1)	SI2373681T1 (lt)
SM (1)	SMT201700189T1 (lt)
WO (1)	WO2010068735A1 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2373681B1 (en)	2008-12-10	2017-01-18	Glaxosmithkline LLC	Pharmaceutical compositions of albiglutide
WO2011140176A1 (en) *	2010-05-04	2011-11-10	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
US9458214B2 (en)	2011-09-26	2016-10-04	Novartis Ag	Dual function fibroblast growth factor 21 proteins
PL2866825T3 (pl)	2012-07-01	2021-02-22	Novo Nordisk A/S	<div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en)	2012-12-21	2015-06-29	Sanofi Sa	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9849066B2 (en)	2013-04-24	2017-12-26	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
PE20151770A1 (es)	2013-05-28	2015-12-11	Takeda Pharmaceutical	Compuesto peptidico
US20140378374A1 (en) *	2013-06-21	2014-12-25	Glaxosmithkline Intellectual Property (No.2) Limited	Methods of treatment
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TW201613630A (en) *	2014-06-25	2016-04-16	Glaxosmithkline Llc	Pharmaceutical compositions
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10501516B2 (en)	2016-05-24	2019-12-10	Takeda Pharmaceutical Company Limited	Peptide compound
CN118955732A (zh)	2017-09-22	2024-11-15	瑞泽恩制药公司	胰高血糖素样肽1受体激动剂及其用途
IL322968A (en)	2017-10-12	2025-10-01	Novo Nordisk As	Semaglutide in medical treatment
EP4590698A1 (en)	2022-09-21	2025-07-30	Regeneron Pharmaceuticals, Inc.	Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) *	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE417622T1 (de)	1996-08-08	2009-01-15	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
KR100518046B1 (ko)	2000-05-19	2005-10-04	아밀린 파마슈티칼스, 인크.	Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
DE60139944D1 (de)	2000-10-12	2009-10-29	Genentech Inc	Niederviskose konzentrierte proteinformulierungen
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
BR0116024A (pt)	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
US7259233B2 (en)	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
HRP20040343A2 (en)	2001-10-18	2005-08-31	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2277889B1 (en)	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
JP4282485B2 (ja)	2002-01-08	2009-06-24	イーライリリーアンドカンパニー	伸長グルカゴン様ペプチド−１アナログ
JP2005535569A (ja)	2002-04-04	2005-11-24	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１アゴニスト及び心臓血管合併症
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514035A (ja)	2002-12-17	2006-04-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	心不整脈の予防および治療
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2316446A1 (en)	2004-06-11	2011-05-04	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
WO2006010143A2 (en)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
SG158158A1 (en)	2004-12-22	2010-01-29	Centocor Inc	Glp-1 agonists, compositions, methods and uses
EP1838336A2 (en)	2004-12-24	2007-10-03	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
DK1888094T3 (da)	2005-03-31	2009-11-09	Amylin Pharmaceuticals Inc	Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser
AU2006235183B2 (en) *	2005-04-08	2011-02-10	Amylin Pharmaceuticals, Llc	Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
DK1888103T3 (da)	2005-04-11	2012-04-23	Amylin Pharmaceuticals Inc	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
HRP20160866T1 (hr)	2005-11-04	2016-10-07	Glaxosmithkline Llc	Postupci primjene hipoglikemijskih sredstava
EP2636680A3 (en)	2006-05-26	2013-12-11	Amylin Pharmaceuticals, LLC	Composition and methods for treatment of congestive heart failure
WO2007139589A1 (en)	2006-05-26	2007-12-06	Bristol-Myers Squibb Company	Sustained release glp-1 receptor modulators
WO2008011446A2 (en)	2006-07-18	2008-01-24	Centocor, Inc.	Human glp-1 mimetibodies, compositions, methods and uses
EP2068910A2 (en)	2006-08-04	2009-06-17	Amylin Pharmaceuticals, Inc.	Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
PE20080840A1 (es)	2006-09-13	2008-08-27	Smithkline Beecham Corp	Metodos para administrar agentes hipoglucemiantes de larga duracion
EP2163243A1 (en)	2008-09-12	2010-03-17	Biocompatibles UK Limited	Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
EP2373681B1 (en)	2008-12-10	2017-01-18	Glaxosmithkline LLC	Pharmaceutical compositions of albiglutide

2009
- 2009-12-10 EP EP09832522.8A patent/EP2373681B1/en active Active
- 2009-12-10 HR HRP20170478TT patent/HRP20170478T1/hr unknown
- 2009-12-10 PL PL09832522T patent/PL2373681T3/pl unknown
- 2009-12-10 WO PCT/US2009/067469 patent/WO2010068735A1/en not_active Ceased
- 2009-12-10 DK DK09832522.8T patent/DK2373681T3/en active
- 2009-12-10 US US13/133,976 patent/US8748377B2/en not_active Expired - Fee Related
- 2009-12-10 ES ES09832522.8T patent/ES2620610T3/es active Active
- 2009-12-10 HU HUE09832522A patent/HUE031900T2/en unknown
- 2009-12-10 SI SI200931639A patent/SI2373681T1/sl unknown
- 2009-12-10 SM SM20170189T patent/SMT201700189T1/it unknown
- 2009-12-10 PT PT98325228T patent/PT2373681T/pt unknown
- 2009-12-10 LT LTEP09832522.8T patent/LT2373681T/lt unknown
- 2009-12-10 JP JP2011540882A patent/JP2012511586A/ja active Pending
2014
- 2014-04-25 US US14/261,641 patent/US20140228284A1/en not_active Abandoned
- 2014-04-25 US US14/261,602 patent/US20140228288A1/en not_active Abandoned
2017
- 2017-03-16 CY CY20171100337T patent/CY1118731T1/el unknown

Also Published As

Publication number	Publication date
SI2373681T1 (sl)	2017-05-31
EP2373681B1 (en)	2017-01-18
SMT201700189T1 (it)	2017-05-08
ES2620610T3 (es)	2017-06-29
CY1118731T1 (el)	2017-07-12
WO2010068735A1 (en)	2010-06-17
US20140228288A1 (en)	2014-08-14
US20140228284A1 (en)	2014-08-14
PT2373681T (pt)	2017-04-11
HUE031900T2 (en)	2017-08-28
EP2373681A1 (en)	2011-10-12
PL2373681T3 (pl)	2017-07-31
US8748377B2 (en)	2014-06-10
US20110301080A1 (en)	2011-12-08
EP2373681A4 (en)	2013-11-06
HRP20170478T1 (hr)	2017-05-19
DK2373681T3 (en)	2017-04-24
JP2012511586A (ja)	2012-05-24

Publication	Publication Date	Title
LT2373681T (lt)	2017-04-10	Albiglutido farmacinės kompozicijos
GB0814695D0 (en)	2008-09-17	Pharmaceutical compositions
PL2323623T3 (pl)	2017-04-28	Kompozycje farmaceutyczne
IL228817A0 (en)	2013-12-31	Pharmaceutical compounds
IL211886A0 (en)	2011-06-30	Solid pharmaceutical composition
IL208387A0 (en)	2010-12-30	Pharmaceutical composition
ZA201104670B (en)	2012-03-28	Pharmaceutical composition comprising aleglitazar
ZA201100871B (en)	2012-05-30	Solid pharmaceutical composition
EP2296687A4 (en)	2012-12-26	PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
IL206487A0 (en)	2010-12-30	Pharmaceutical compositions
ZA201006224B (en)	2011-11-30	Pharmaceutical composition
ZA201101053B (en)	2012-07-25	Pharmaceutical compositions of samatotrophic hormones
GB2464200B (en)	2013-05-08	Pharmaceutical composition
GB0902648D0 (en)	2009-04-01	Pharmaceutical compounds and compositions
GB0817969D0 (en)	2008-11-05	Pharmaceutical composition
GB0908317D0 (en)	2009-06-24	Pharmaceutical compounds and compositions
GB0800659D0 (en)	2008-02-20	Pharmaceutical Compositions
EP2236135A4 (en)	2012-05-02	STABLE PHARMACEUTICAL COMPOSITION
GB0804485D0 (en)	2008-04-16	Novel pharmaceutical compositions
GB0805807D0 (en)	2008-04-30	Novel pharmaceutical compositions
GB0806283D0 (en)	2008-05-14	Pharmaceutical compositions
GB0802024D0 (en)	2008-03-12	Pharmaceutical compositions
GB0806156D0 (en)	2008-05-14	Pharmaceutical compositions
EP2308842A4 (en)	2012-03-14	PHARMACEUTICAL COMPOSITIONS
HU0800741D0 (en)	2009-03-02	Improved pharmaceutical composition